CommentaryBenefits of Dexmedetomidine in Management of Post-ECT AgitationNarang, Puneet MD*†; Ianovich, Francesca BS*; Sarai, Simrat Kaur MD‡; Lippmann, Steven MD‡Author Information From the *University of Minnesota; †Regions Hospital, Minneapolis-St Paul, MN; and ‡University of Louisville School of Medicine, Louisville, KY. Received for publication November 30, 2016; accepted January 1, 2017. Reprints: Puneet Narang, MD, Regions Hospital, 640 Jackson St, St Paul, MN 55101 (e-mail: [email protected]). The authors have no conflicts of interest or financial disclosures to report. The Journal of ECT: September 2017 - Volume 33 - Issue 3 - p 150-151 doi: 10.1097/YCT.0000000000000393 Buy Metrics Abstract Electroconvulsive therapy (ECT) is an intervention for patients with a variety of psychiatric conditions. Occasionally, people exhibit dangerous degrees of agitation after this treatment, and some do not respond well to conventional pharmacotherapies. Dexmedetomidine is a central α-2 agonist that can induce significantly calmative effects in persons with post-ECT agitation. The indication for it is in calming individuals with acute and/or recurrent posttreatment agitation. Dexmedetomidine is safe and effective when infused just before, or postictally, at ECT sessions. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.